Enterprise Value

-1.017M

Cash

8.403M

Avg Qtr Burn

-882.6K

Short % of Float

0.85%

Insider Ownership

46.72%

Institutional Own.

3.63%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tecarfarin Details
End-Stage Renal Disease , Systemic thromboembolism, Atrial fibrillation

Phase 3

Initiation